19532-41-3 Usage
Uses
Used in Pharmaceutical Industry:
1–(4-bromophenyl)-1H-pyrazole-3-carboxylic acid is used as a pharmaceutical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs, contributing to the creation of innovative treatments for various medical conditions.
Used in Chemical Industry:
In the chemical industry, 1–(4-bromophenyl)-1H-pyrazole-3-carboxylic acid may have applications beyond pharmaceuticals. Its bromine-substituted phenyl group and pyrazole carboxylic acid structure could be utilized in the synthesis of other chemical products, such as dyes, agrochemicals, or materials with specific properties for various industrial applications.
Used in Drug Development:
1–(4-bromophenyl)-1H-pyrazole-3-carboxylic acid is used as a key component in the development of new drugs. Its potential therapeutic properties are being studied, and it may contribute to the discovery of novel treatments for a range of diseases and conditions. 1–(4-bromophenyl)-1H-pyrazole-3-carboxylic acid's versatility and unique structure make it a promising candidate for further research and development in the pharmaceutical sector.
Check Digit Verification of cas no
The CAS Registry Mumber 19532-41-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,5,3 and 2 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 19532-41:
(7*1)+(6*9)+(5*5)+(4*3)+(3*2)+(2*4)+(1*1)=113
113 % 10 = 3
So 19532-41-3 is a valid CAS Registry Number.
19532-41-3Relevant academic research and scientific papers
Magalh?es, Joana,Franko, Nina,Annunziato, Giannamaria,Welch, Martin,Dolan, Stephen K.,Bruno, Agostino,Mozzarelli, Andrea,Armao, Stefano,Jirgensons, Aigars,Pieroni, Marco,Costantino, Gabriele,Campanini, Barbara
, p. 1444 - 1452 (2018)
Several bacteria rely on the reductive sulphur assimilation pathway, absent in mammals, to synthesise cysteine. Reduction of virulence and decrease in antibiotic resistance have already been associated with mutations on the genes that codify cysteine biosynthetic enzymes. Therefore, inhibition of cysteine biosynthesis has emerged as a promising strategy to find new potential agents for the treatment of bacterial infection. Following our previous efforts to explore OASS inhibition and to expand and diversify our library, a scaffold hopping approach was carried out, with the aim of identifying a novel fragment for further development. This novel chemical tool, endowed with favourable pharmacological characteristics, was successfully developed, and a preliminary Structure–Activity Relationship investigation was carried out.
